Patent US11992513B2, granted in May 2024, encodes the core cardiovascular evidence from the SUSTAIN-6 trial into method-of-treatment claims. Semaglutide administered once weekly for at least 2 years in patients with type 2 diabetes and a history of established cardiovascular disease reduced the risk of the MACE composite endpoint — cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke — by 26%.

Critically, the individual components showed differential benefit: cardiovascular death was reduced by 26%, nonfatal myocardial infarction by 26%, and nonfatal stroke by 39%. The stroke reduction figure is particularly notable and is explicitly encoded in patent claims, providing Novo Nordisk with a specific defensible claim for stroke prevention in T2D patients with established CVD.

Secondary renal endpoints from SUSTAIN-6 and PIONEER-6 trials also demonstrated significant reductions in new or worsening nephropathy and persistent macroalbuminuria in the semaglutide arm versus placebo — data that now underpins the FLOW trial's renal composite endpoint claims. Life sciences IP teams should note that these secondary endpoints are now being elevated to primary claims in the 2024 filing cohort.

The WO2024160884A1 filing — published August 2024 — is the most comprehensive cardiorenal claim yet, covering both the FLOW trial population (T2D with CKD) and the SELECT trial population (non-T2D with obesity/overweight and CVD history) under a unified cardiorenal composite endpoint framework including MACE, CKD progression, renal replacement therapy, and cardiovascular death.

The convergence of SELECT, FLOW, and SOUL trial data transforms semaglutide from a diabetes and obesity drug into a cardiorenal platform asset. The WO2024160884A1 filing — covering both the FLOW and SELECT populations under a unified cardiorenal composite endpoint — is the clearest signal yet that Novo Nordisk is pursuing a single broad label encompassing obesity, T2D, CKD, and cardiovascular disease simultaneously.

For payers and health technology assessment bodies, the implication is significant: a single agent with demonstrated outcomes across MACE, CKD progression, renal replacement therapy, and cardiovascular death creates a compelling cost-effectiveness argument that is difficult to challenge with existing standard-of-care agents alone. WHO and national health agencies are already tracking GLP-1 cardiorenal evidence for formulary decisions.

For competitors, the 2024 filing cohort signals that the window for establishing blocking positions in the cardiorenal GLP-1 space is narrowing rapidly. Novo Nordisk's patent analytics position is anchored by method-of-treatment claims that are population-specific and outcome-specific — making design-around strategies difficult without distinct clinical evidence. EMA and FDA regulatory submissions will be closely watched for label language that mirrors or extends the patent claim scope.

The NASH/NAFLD filings (WO2022063874A1, WO2024008810A1) represent the next frontier beyond cardiorenal — with semaglutide 2.4 mg claims covering NASH-related fibrosis, cirrhosis, liver failure, hepatocellular carcinoma, and liver fat reduction. Organisations tracking life sciences IP strategy should monitor this cluster as a potential fourth major indication expansion alongside the cardiorenal trilogy.